MX2019010937A - Combinacion entre trifluridina/hidrocloruro de tipiracilo, un complejo de platino antitumoral, y un modulador del punto de control inmune. - Google Patents

Combinacion entre trifluridina/hidrocloruro de tipiracilo, un complejo de platino antitumoral, y un modulador del punto de control inmune.

Info

Publication number
MX2019010937A
MX2019010937A MX2019010937A MX2019010937A MX2019010937A MX 2019010937 A MX2019010937 A MX 2019010937A MX 2019010937 A MX2019010937 A MX 2019010937A MX 2019010937 A MX2019010937 A MX 2019010937A MX 2019010937 A MX2019010937 A MX 2019010937A
Authority
MX
Mexico
Prior art keywords
combination
immune checkpoint
trifluridine
platinum complex
checkpoint modulator
Prior art date
Application number
MX2019010937A
Other languages
English (en)
Inventor
Bruno Alain
Cattan Valérie
Frank Burbridge Michaël
Abastado Jean-Pierre
AMELLAL Nadia
Leger Catherine
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2019010937A publication Critical patent/MX2019010937A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una combinación entre: fármaco FTD-TPI, un complejo de platino antitumoral y un modulador del punto de control inmune. Medicamentos correspondientes.
MX2019010937A 2017-03-17 2018-03-16 Combinacion entre trifluridina/hidrocloruro de tipiracilo, un complejo de platino antitumoral, y un modulador del punto de control inmune. MX2019010937A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17161630 2017-03-17
PCT/EP2018/056632 WO2018167256A1 (en) 2017-03-17 2018-03-16 Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator

Publications (1)

Publication Number Publication Date
MX2019010937A true MX2019010937A (es) 2019-10-24

Family

ID=58387699

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010937A MX2019010937A (es) 2017-03-17 2018-03-16 Combinacion entre trifluridina/hidrocloruro de tipiracilo, un complejo de platino antitumoral, y un modulador del punto de control inmune.

Country Status (11)

Country Link
US (1) US20200009104A1 (es)
EP (1) EP3595716A1 (es)
JP (1) JP7168575B2 (es)
CN (1) CN110402151A (es)
AU (1) AU2018234141A1 (es)
CA (1) CA3056485A1 (es)
MA (1) MA49882A (es)
MX (1) MX2019010937A (es)
TW (1) TWI671072B (es)
WO (1) WO2018167256A1 (es)
ZA (1) ZA201905546B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019171394A1 (en) * 2018-03-03 2019-09-12 Natco Pharma Limited Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0763529T3 (da) 1995-03-29 2003-11-10 Taiho Pharmaceutical Co Ltd Uracilderivater og antitumorvirkningspotentiator og antitumormiddel indeholdende samme
RS62560B1 (sr) * 2014-04-04 2021-12-31 Taiho Pharmaceutical Co Ltd Antitumorski lek koji sadrži antitumorski kompleks platine, i pojačivač antitumorskog efekta

Also Published As

Publication number Publication date
MA49882A (fr) 2020-06-24
EP3595716A1 (en) 2020-01-22
AU2018234141A1 (en) 2019-09-12
RU2019131581A (ru) 2021-04-19
WO2018167256A1 (en) 2018-09-20
ZA201905546B (en) 2021-05-26
RU2019131581A3 (es) 2021-07-12
TW201836616A (zh) 2018-10-16
TWI671072B (zh) 2019-09-11
CA3056485A1 (en) 2018-09-20
JP2020510058A (ja) 2020-04-02
JP7168575B2 (ja) 2022-11-09
US20200009104A1 (en) 2020-01-09
CN110402151A (zh) 2019-11-01

Similar Documents

Publication Publication Date Title
MY194032A (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
ZA202102696B (en) Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
HK1247210A1 (zh) 包含針對密封蛋白18.2之抗體的藥物綴合物
NI201800038S (es) Dispositivo de administración de medicamento intranasal
GB202002677D0 (en) Beamed elastomeric laminate structure, fit, and textute
SG10201902350XA (en) Devices, systems and methods for using and monitoring medical devices
JOP20190161A1 (ar) مستشعرات جلوكوز بطيف قريب من الأشعة تحت الحمراء
EP3675932A4 (en) SYSTEMS, METHODS, APPARATUS AND DEVICES FOR THE ADMINISTRATION OF THE MEDICINAL PRODUCT OR SUBSTANCE
SG11201811571WA (en) Discharge device and method for manufacturing same
EP3618916A4 (en) ROBUST IMPLANTABLE GAS DISPENSING DEVICE AND PROCEDURES, SYSTEMS AND DEVICES THEREFORE
MX2018008407A (es) Dispositivo secundario.
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
EP3699957A4 (en) MODULE AND SERVER
EP3556771A4 (en) CLAUDINE 5 ANTIBODIES AND MEDICINE CONTAINING SAME
MX2023006458A (es) Oligosacaridos inmunomoduladores.
MX2018007231A (es) Una composicion antimicrobiana.
SG11202011232VA (en) Anti-cd63 antibodies, conjugates, and uses thereof
MX2020005472A (es) Sistemas de administración de fármacos a base de maitansinoide.
EP3623384A4 (en) ANTI-CLDN-5 ANTIBODIES, AND THE MEDICINAL PRODUCT CONTAINING IT
EP3647234A4 (en) PROJECTION INDICATION DEVICE, LUGGAGE SORTING SYSTEM, AND PROJECTION INDICATION PROCESS
CA172157S (en) Cannula pad
MX2019010937A (es) Combinacion entre trifluridina/hidrocloruro de tipiracilo, un complejo de platino antitumoral, y un modulador del punto de control inmune.
EP3766536A4 (en) MEDICATION DELIVERY DEVICE, APPARATUS AND SET
EP3700312A4 (en) MODULE AND SERVER
EP3875419A4 (en) MECHANICAL CURBSIDE DISPLAY DEVICE AND MECHANICAL CURBSIDE